EGFR and neoplasm: Although a relationship between sensitivity to EGFR TKIs and tumor E-cadherin expression has been proposed, depletion of cadherin 1 (CDH1) by itself in EGFR-mutant therapy-naïve NSCLC cells does not lead to a loss of EGFR TKI efficacy [31].